** Pharmaceutical stocks slide 1.8% after U.S. President Donald Trump signals "major" tariff on pharma imports soon
** Nifty Pharma .NIPHARM index down 6.3% since April 4 when Trump first threatened the duties, ending the sector's brief reprieve
** According to Trump, the pharma duty will incentivise drug cos to move operations to the U.S.
** NIPHARM's all 20 constituents in the red; Gland Pharma GLAD.NS, Dr Reddy's Laboratories REDY.NS, Lupin LUPN.NS, IPCA Laboratories IPCA.NS lose between 2%-4.3%
** Sub-index extends YTD losses to 14.4% vs Nifty 50's .NSEI 5.1% fall
(Reporting by Aleef Jahan in Bengaluru)
((aleefjahan.cs@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。